CSF3R and Splenomegaly: It was also identified that the CSF3R T618I mutation exerted its effect through the JAK-STAT signaling pathway; hence, the splenomegaly and granulocytosis were responsive to treatment with ruxolitinib, a JAK inhibitor [5,6,9,11].